![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Medgenics(Regs) | LSE:MEDG | London | Ordinary Share | COM SHS USD0.0001 (REGS) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 302.50 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMMEDG RNS Number : 2692N Medgenics Inc 09 June 2010 MEDGENICS ENHANCES STRATEGIC ADVISORY BOARD Misgav, Israel and London, UK -9 June 2010 - Medgenics, Inc. (AIM: MEDG, MEDU), the company that has developed a novel technology for the manufacture and delivery of therapeutic proteins continuously in patients using their own tissue, announces the addition of a highly experienced Pharmaceutical Executive, Mr. Burt Rosen, to its Strategic Advisory Board. As the Company further develops its technology platform, a competency in dealing with the regulatory and reimbursement issues becomes highly desirable. As a result, the Company has decided to expand its Scientific Advisory Board to include members that possess a wider range of professional and commercial skills that will be required for the Company going forward. Burt Rosen is a serial entrepreneur with over 20 years' experience. Burt has developed and implemented Federal, State, and Communications strategies for five major pharmaceutical and consumer product companies. Prior to its sale to Johnson & Johnson in 2009 for $1.17B, Burt served on the Board of Directors of Mentor Corporation, an NYSE listed medical device company. In his current position as Vice President of Federal Government Relations for Purdue Pharmaceuticals, Burt's primary responsibilities include providing strategic advice and leadership to the senior management of that company, and to act as Chairman of its Issues Co-ordinating Team. Burt has been active in the government relations and communications industries since 1978, and has worked for such high profile companies as SmithKline Beecham (now GlaxoSmithKline), Bristol-Myers Squibb and Novartis. His duties have ranged from developing legislation to identifying potential licensing and strategic opportunities. The Board of Directors of Medgenics believes that the addition of Burt will provide valuable assistance to the Company as it pursues partnering opportunities and seeks regulatory approval, reimbursement from third party payers (government and private) and sourcing of advocacy groups. The Board further believes that he will be a key asset in strategic planning with extensive contacts and many years of experience as a senior executive in the pharmaceutical industry. Commenting on the appointment, Dr Andrew Pearlman, CEO of Medgenics said: 'We are delighted by this new appointment and believe that Burt's extensive contacts among senior pharmaceutical executives will complement the work of our top team leading our business development programme. In addition, the regulatory and lobbying expertise among government and patient advocacy groups will be invaluable as we seek to fully commercialise the Medgenics technology.' For further information, contact: +----------------------------------+--------------------------+ | Medgenics, Inc. | Phone: +972 4 902 8900 | | Dr. Andrew L. Pearlman | | | | | +----------------------------------+--------------------------+ | De Facto Communications | Phone: +44 207 861 3838 | | Mike Wort | | | Anna Dunphy | | | | | +----------------------------------+--------------------------+ | Religare Capital Markets (Nomad) | Phone: +44 207 444 0800 | | James Pinner | | | Derek Crowhurst | | | | | +----------------------------------+--------------------------+ +----------------------------------+--------------------------+ | SVS Securities plc (Joint | Phone: +44 207 638 5600 | | Broker) | | | Alex Mattey | | | Ian Callaway | | | | | +----------------------------------+--------------------------+ +----------------------------------+--------------------------+ | Nomura Code Securities (Joint | Phone: +44 207 776 1219 | | Broker) | | | Jonathan Senior | | | | | | | | +----------------------------------+--------------------------+ This information is provided by RNS The company news service from the London Stock Exchange END MSCUGUQPQUPUGCR
1 Year Medgenics(Regs) Chart |
1 Month Medgenics(Regs) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions